ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Subscribe To Our Newsletter & Stay Updated
